INZY - Inozyme Pharma partners with genomic medicine institute for newborn screenings

Inozyme Pharma (NASDAQ:INZY) will work with the Rady Children’s Institute for Genomic Medicine to evaluate a novel newborn screening technology that can help diagnose genetic diseases. Rady has BeginNGS, a precision medicine tool that involves rapid Whole Genome Sequencing to screen newborns for around 400 genetic diseases. The pilot program hopes to expand to screen for 1K diseases, sequence 3.7M newborns per year, and become the genetic disease screening standard for newborns. Inozyme's (INZY) focus in on rare mineralization disorders. It has one candidate in the clinic, INZ-701, for ENPP1 and ABCC6 deficiencies. Inozyme recently appointed a new chief medical officer.

For further details see:

Inozyme Pharma partners with genomic medicine institute for newborn screenings